Arcutis Biotherapeutics Expands Board to Ten Directors With Appointment of Christopher Peetz

Background on Christopher Peetz and Board Selection

Christopher Peetz joins Arcutis Biotherapeutics with a track record of leadership spanning multiple stages of biopharmaceutical development and commercialization. The appointment announcement indicates that Peetz has served as Chief Executive Officer of Mirum Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, since March 2019, and held the position of President from November 2018 to January 2024. His professional background extends across several notable companies in the life sciences sector, demonstrating deep expertise in both operational and strategic functions within the industry.

Prior to his tenure at Mirum Pharmaceuticals, Peetz served as Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. The disclosure also notes his prior experience as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a publicly-traded biotechnology company that was acquired by Allergan plc. in November 2016. His educational credentials include an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in finance, international business, and French from Washington University in St. Louis. The Board determined that Peetz qualifies as an independent director under applicable Securities and Exchange Commission rules and Nasdaq listing standards.

Comprehensive Professional Experience in Biopharmaceutical Development

Peetz's career history reflects progressive responsibility within biopharmaceutical enterprises of varying sizes and development stages. The disclosure states that prior to joining Tobira Therapeutics, he served as Vice President of Finance and Corporate Development at Jennerex Biotherapeutics, Inc., a biopharmaceutical company. His earlier career included multiple positions at Onyx Pharmaceuticals, Inc., now part of Amgen Inc., where he worked in corporate strategy, marketing, product lifecycle management, and financial planning roles. This combination of finance, strategy, and commercial expertise provides relevant background for board-level oversight of biopharmaceutical operations.

Beyond his primary executive roles, Peetz has maintained involvement with the broader biopharmaceutical ecosystem. The filing discloses that he served as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, from April 2018 until its sale to Vertex in May 2024. Additionally, he has served as an entrepreneur-in-residence at Frazier Life Sciences since May 2017. Early in his career, he provided merger and acquisition advisory services at LaSalle Corporate Finance, a division of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc., further demonstrating exposure to corporate development and strategic transactions in life sciences.

Board Structure and Independence Standards

The Board of Directors determined that Christopher Peetz meets the independence requirements established by the Securities and Exchange Commission and The Nasdaq Stock Market LLC. As a Class III director, Peetz's term will expire at the Company's 2029 annual meeting of stockholders or until his successor is duly elected and qualified, or upon his earlier death, resignation, disqualification, or removal. The disclosure confirms that the Board has not appointed Peetz to any committee of the Board at this time, allowing for potential future committee assignments as the company's governance structure evolves.

The appointment process followed standard corporate governance procedures. The filing states that there is no arrangement or understanding between Peetz and any other person pursuant to which he was selected as a director. Additionally, there are no family relationships between Peetz and any of the Company's directors or executive officers. The disclosure also confirms that there are no transactions to which Arcutis Biotherapeutics is a party and in which Peetz has a direct or indirect material interest that would be required to be disclosed under applicable Securities and Exchange Commission regulations.

Director Compensation Structure and Equity Awards

As a non-employee director, Peetz will receive compensation in accordance with Arcutis Biotherapeutics' non-employee director compensation program. Upon the effective date of his appointment to the Board, the disclosure states that Peetz received an initial stock option award exercisable for 21,486 shares of the Company's common stock. This initial award will vest in three equal annual installments on the anniversary of the date of Peetz's appointment to the Board, subject to his continued service to the Company through each vesting date.

Beyond the initial option award, Peetz is eligible for a prorated annual equity award that is fair valued at approximately $350,000. The disclosure specifies that this annual equity compensation is allocated 65% to stock options and 35% to restricted stock units. The prorated portion of this annual equity award will vest immediately before the annual meeting following the grant date, again contingent on Peetz's continued service to the Company through that date. Additionally, Peetz is eligible for the prorated portion of the annual cash retainer in the amount of $50,000 for service on the Board. These compensation arrangements align with the company's established non-employee director compensation program.

Indemnification Agreement and Governance Framework

Arcutis Biotherapeutics will enter into an indemnification agreement with Christopher Peetz on the form previously approved by the Board and entered into with the Company's other directors. This standard governance practice provides protection to directors in connection with their service to the company and reflects Arcutis's commitment to maintaining consistent director protections across its Board. The indemnification agreement framework has been previously established and approved by the Board, ensuring consistency in director treatment and governance practices.

The appointment of Peetz represents the company's ongoing effort to maintain an effective and experienced Board of Directors capable of providing oversight and strategic guidance. The increase in Board size from nine to ten directors provides additional capacity for board committee work and specialized expertise across Arcutis Biotherapeutics' operations. The formal governance documentation, including the indemnification agreement and compensation arrangements, reflects the company's adherence to established corporate governance protocols and regulatory requirements.

Company Background and Market Context

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company headquartered in Westlake Village, California, with a focus on dermatological treatments. The company's operations and strategic direction benefit from board-level oversight of clinical development, regulatory matters, and commercial execution. The appointment of a director with substantial experience in both clinical-stage and commercial-stage biopharmaceutical companies provides relevant expertise for a firm navigating the complexities of bringing therapies to market and managing commercial operations.

The timing of this Board expansion and the selection of a director with proven experience in company leadership and commercial development suggest that Arcutis Biotherapeutics is positioning itself for continued advancement in its business objectives. Peetz's background in finance, corporate development, and executive leadership across multiple biopharmaceutical organizations provides skills that are directly applicable to the challenges and opportunities facing the company. His experience with publicly-traded biopharmaceutical companies and exposure to merger and acquisition activity within the sector add additional dimensions to the Board's collective expertise.

Announcement and Public Disclosure

On July 16, 2026, Arcutis Biotherapeutics issued a press release announcing the appointment of Christopher Peetz to the Board of Directors. This announcement was made one day after the Board's formal action on July 15, 2026, allowing for timely communication to shareholders, investors, and other stakeholders. The public announcement reflects the company's commitment to transparent corporate governance and timely disclosure of material board changes to the investment community.

The current disclosure constitutes a Form 8-K current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The announcement and supporting materials were filed with the Securities and Exchange Commission, making the information part of the company's official regulatory record. This formal disclosure mechanism ensures that investors have access to material information regarding changes in board composition and the qualifications of new directors, supporting informed investment decision-making.

Strategic Implications for Shareholders

The expansion of Arcutis Biotherapeutics' Board from nine to ten members and the appointment of Christopher Peetz provide investors with insight into the company's governance priorities and strategic direction. The selection of a director with extensive experience in biopharmaceutical executive leadership, including roles as Chief Executive Officer at both clinical and commercial-stage companies, suggests that the company values operational expertise and strategic business management among its board members. Peetz's background in financial planning, corporate development, and merger and acquisition activity may also indicate areas of focus for the company's future strategic initiatives.

Investors may be watching how Peetz's appointment influences board committee assignments and the company's strategic priorities moving forward. His experience with publicly-traded biopharmaceutical companies and previous board service at Alpine Immune Sciences provide him with relevant exposure to capital markets dynamics and investor relations considerations. The appointment reflects the company's commitment to maintaining a Board capable of overseeing complex biopharmaceutical operations and advancing shareholder value through effective governance and strategic oversight.